Details

Autor(en) / Beteiligte

• Kolstad, A.
• Nome, O.
• Delabie, J.
• Lauritzsen, G. F.
• Fossa, A.
• Holte, H.

Titel

Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma

Ist Teil von

• Leukemia & lymphoma, 2007-01, Vol.48 (3), p.570-576

Ort / Verlag

United States: Informa UK Ltd

Erscheinungsjahr

2007

Quelle

Taylor & Francis

Beschreibungen/Notizen

• There is no consensus on the optimal chemotherapy regimen for Hodgkin's lymphoma patients ≥ 60 years. We present our institution's results of 5 years, using CHOP-21 as standard for this patient group. Twenty-nine patients with a median age of 71 years (range, 60 - 91) were included in this cohort. Fifty-five percent had known co-morbidities. Stage I IIA patients (38%) were treated with 2 - 4 cycles of CHOP followed by radiotherapy. Stage IIB - IV patients (62%) received 6 - 8 cycles of CHOP and for the majority (13 18 pts) no radiotherapy. Two treatment-related deaths occurred. Febrile neutropenia was the most common toxicity (31%). The complete response rate after CHOP + − radiotherapy was 93%. With a median follow-up of 41 months, five patients have relapsed and four have died from Hodgkin's lymphoma. So far, no relapses have occurred after 2 years from the end of therapy. Overall survival and progression-free survival at 3 years were 79% and 76%, respectively. We conclude that CHOP-21 is a well-tolerated and effective treatment for elderly patients with Hodgkin's lymphoma.